Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (UTOPIA)

Intravenous Tenecteplase for Acute Ischemic Stroke With Unknown Time of Onset Under Non-Contrast CT Selection: A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Trial

The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic stroke with unknown time of onset.

Study Overview

Detailed Description

UTOPIA is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial that aims to assess the efficacy and safety of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, selected by non-contrast CT. The primary outcome is excellent outcome, as defined by a score of 0 or 1 on modified Rankin Scale (mRS) at 90 days.

Participants randomized to the intervention group will receive intravenous tenecteplase at 0.25 mg/kg with a maximum dose of 25 mg and standard medical treatment, and those randomized to the control group will receive standard medical treatment only, without intravenous thrombolysis.

Study Type

Interventional

Enrollment (Estimated)

352

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Fujian
      • Xiamen, Fujian, China, 361004
        • Not yet recruiting
        • Zhongshan Hospital of Xiamen University
        • Contact:
          • Xingyu Chen
    • Guangdong
      • Guangzhou, Guangdong, China, 510620
        • Not yet recruiting
        • Guangzhou Twelfth People's Hospital
        • Contact:
          • Jianwu Dai
    • Guangxi
      • Baise City, Guangxi, China, 533000
        • Not yet recruiting
        • Baise People's Hospital
        • Contact:
          • Dengxing Li
      • Chongzuo, Guangxi, China, 532200
        • Recruiting
        • The People's Hospital of Chongzuo
        • Contact:
          • Jianyi Huang
      • Guigang, Guangxi, China, 537121
        • Not yet recruiting
        • People's Hospital of Qintang District, Guigang City
        • Contact:
          • Jixin Lu
      • Guigang, Guangxi, China, 537200
        • Not yet recruiting
        • Guiping People's Hospital
        • Contact:
          • Peiquan Yang
      • Laibin, Guangxi, China, 545900
        • Not yet recruiting
        • Wuxuan County People's Hospital
        • Contact:
          • Yu Huang
      • Liuzhou, Guangxi, China, 545007
        • Not yet recruiting
        • Liuzhou Workers' Hospital
        • Contact:
          • Liya Pan
      • Nanning, Guangxi, China, 530021
        • Not yet recruiting
        • The First Affiliated Hospital of Guangxi Medical University
        • Contact:
        • Principal Investigator:
          • Yuan Wu, MD, PhD
      • Nanning, Guangxi, China, 530200
        • Not yet recruiting
        • Nanning Yongning District People's Hospital
        • Contact:
          • Wuqiao Liang
        • Contact:
          • Qihai Zhou
      • Nanning, Guangxi, China, 530219
        • Not yet recruiting
        • Guangxi Medical University Kaiyuan Langdong Hospital
        • Contact:
          • Kai Chen
      • Nanning, Guangxi, China, 530409
        • Not yet recruiting
        • No.9 People's Hospital of Nanning
        • Contact:
          • Jun Qu
      • Qinzhou, Guangxi, China, 535000
        • Not yet recruiting
        • The Second People's Hospital of Qinzhou
        • Contact:
          • Caixia Xuan
    • Shaanxi
      • Yulin, Shaanxi, China, 718100
        • Not yet recruiting
        • Mizhi County Hospital
        • Contact:
          • Tao Zhang
      • Yulin, Shaanxi, China, 718600
        • Not yet recruiting
        • Dingbian County People's Hospital
        • Contact:
          • Gaiyan Qu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age ≥ 18 years old.
  2. Clinical diagnosis of acute ischemic stroke.
  3. Unknown time of stroke onset (e.g., stroke symptom recognized on awakening) but last-known normal time >4.5 hours.
  4. Time from stroke symptom recognition (e.g., awakening) to randomization within 3 hours.
  5. National Institutes of Health Stroke Scale (NIHSS) score of 6-25 (both inclusive).
  6. Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  7. Written informed consent from patients or their legally authorized representatives.

Exclusion Criteria:

  1. Intracranial hemorrhage confirmed by skull CT, or history of intracranial hemorrhage.
  2. Planned endovascular treatment.
  3. Rapid neurological improvement with NIHSS <6 at randomization.
  4. Allergy to tenecteplase.
  5. Use of vitamin K antagonist with INR >1.7, use of heparin or low molecular heparin in the past 24 hours, or use of direct oral anticoagulants in the past 48 hours.
  6. Hypodensity on non-contrast CT >1/3 middle cerebral artery territory.
  7. Severe traumatic brain injury or other major trauma in the past 3 months.
  8. Intracranial neoplasm, arteriovenous malformation, or aneurysm (≥10mm).
  9. Intracranial surgery, intraspinal surgery, or other major surgery in the past 3 months.
  10. Gastrointestinal or urinary tract hemorrhage in the past 3 weeks.
  11. Active internal bleeding.
  12. Aortic dissection.
  13. Infective endocarditis.
  14. Platelet count <100×10^9/L.
  15. Women who are pregnant or breastfeeding.
  16. Blood glucose <50 or >400 mg/dL (<2.78 or >22.2 mmol/L).
  17. Systolic blood presure >185 mmHg or diastolic blood presure >110 mmHg refractory to treatment.
  18. Life expectancy <3 months.
  19. Participating in other trials.
  20. Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Control group

Standard Medical Treatment

Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators.

Experimental: Tenecteplase group

Intravenous tenecteplase thrombolysis

Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators.

Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Excellent outcome
Time Frame: 90 (±14) days

The proportion of modified Rankin Scale (mRS) score of 0-1 at 90 days

90 (±14) days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Level of disability
Time Frame: 90 (±14) days

Ordinal shift analysis of the mRS with 5-6 merged at 90 days.

90 (±14) days
Functional independence
Time Frame: 90 (±14) days

The proportion of mRS score of 0-2 at 90 days.

90 (±14) days
Early neurological improvement
Time Frame: 24 (±12) hours

The proportion of NIHSS 0-1 or ≥4 points reduction at 24 (±12) hours.

24 (±12) hours
Change in stroke severity
Time Frame: 7 (±1) days or at discharge

The change of NIHSS score from baseline to 7 days or at discharge (whichever comes first)

7 (±1) days or at discharge
Quality of life measured by EQ-5D-5L
Time Frame: 90 (±14) days

EQ-5D-5L scale score at 90 days.

90 (±14) days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptomatic intracranial hemorrhage
Time Frame: 24 (±12) hours

Incidence of symptomatic intracranial hemorrhage within 36 hours from randomization (Heidelberg criteria)

24 (±12) hours
Any intracranial hemorrhage
Time Frame: 24 (±12) hours

Incidence of any intracranial hemorrhage within 36 hours from randomization (Heidelberg classification)

24 (±12) hours
Extracranial bleeding
Time Frame: 24 (±12) hours

Incidence of moderate-to-severe extracranial bleeding (GUSTO criteria) within 36 hours from randomization

24 (±12) hours
Mortality
Time Frame: 90 days

All cause death within 90 days.

90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yuan Wu, MD, PhD, First Affiliated Hospital of Guangxi Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 24, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

March 13, 2026

First Submitted That Met QC Criteria

March 13, 2026

First Posted (Actual)

March 17, 2026

Study Record Updates

Last Update Posted (Actual)

September 30, 2026

Last Update Submitted That Met QC Criteria

September 29, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data supporting the findings of the study are available on reasonable request after approval of a proposal from the principal investigator.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe